Please login to the form below

Not currently logged in
Email:
Password:

Nycomed/Almirall sign China deal

Swiss firm Nycomed has signed an agreement to market Spain-based pharmaceutical company Almirall’s antihistamine Kestine (ebastine) in China and other markets in Southeast Asia

Swiss firm Nycomed has signed an agreement to market Spain-based pharmaceutical company Almirall's antihistamine Kestine (ebastine) in China and other markets in Southeast Asia.

As part of the deal, Nycomed will hold exclusive commercialisation rights for Kestine in China, where the product is already available, as well as rights for the drug once it is launched in Malaysia, Philippines, Singapore, Thailand and Indonesia.

Kestine, prescribed for the treatment of allergic rhinitis and chronic idiopathic urticaria, is already approved for marketing in 30 countries.
Financial details of the agreement were not disclosed.

Guido Oelkers, executive vice president, Commercial Operations at Nycomed explained the deal would support the company's development in Asia.

He said: "Emerging markets continue to be our focus area for future growth."

29th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics